|
| Status |
Public on Nov 15, 2020 |
| Title |
Whole blood, Day 31, PID 15 |
| Sample type |
RNA |
| |
|
| Source name |
Whole blood samples from subject 15 at Day 31
|
| Organism |
Homo sapiens |
| Characteristics |
adjuvant: AS04
subject id: 15
time (sample day): D31
|
| Treatment protocol |
PAXgene preserved whole blood samples were centrifuged, resuspended in lysis buffer and treated with proteinase K.
|
| Growth protocol |
/
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated by PAXgene Blood RNA kit (Qiagen) according to the manufacturer’s protocol. A DNAse treatment was applied on the PAXgene RNA spin column to avoid genomic DNA contamination. RNA was quantified by UV-spectrophotometry.
|
| Label |
Biotin
|
| Label protocol |
Biotinylated cDNA were prepared according to NuGen Ovation WB amplification protocol from 50ng total RNA
|
| |
|
| Hybridization protocol |
After fragmentation, 3.75 ug of cDNA were hybridized for 16 hr at 45C on GeneChip_ Human Genome U133 Plus 2.0 arrays following standard procedures.
|
| Scan protocol |
Data acquisition was performed using GeneChip Operating Software (Affymetrix).
|
| Description |
1 day after 2nd vaccination
|
| Data processing |
The data were analyzed with R/Bioconductor using GCRMA as summarization/normalization method
|
| |
|
| Submission date |
May 14, 2020 |
| Last update date |
Nov 16, 2020 |
| Contact name |
Robbert Gerrit van der Most |
| E-mail(s) |
[email protected]
|
| Organization name |
GSK
|
| Street address |
89, rue de l'Institut
|
| City |
Rixensart |
| ZIP/Postal code |
1330 |
| Country |
Belgium |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE116975 |
Results from analysis of microarray data from clinical trial NCT00805389 |
|
